Gurunadh A Vemulakonda, MD
Ophthalmology · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 14
- 2 carriers
- Office
- 1
Offices
1 location · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Plans that list them
14 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Vemulakonda’s office at (415) 600-1020 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
14 of 14 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A105147 · Current
Licensed to practise in California · since 2008 · expires 2028-03-31 · Washington University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- Washington MD.MD.60022492Physician And Surgeon License · since 2008 · expires 2027-03-08ActiveNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Original Medicare doctor bills
$1,688,412
Medicare paid this office $1,688,412 for 844 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, aflibercept, 1 mg | 128 | $717,754 | None |
| Injection, faricimab-svoa, 0.1 mg | 34 | $264,413 | None |
| Injection, aflibercept hd, 1 mg | 19 | $160,558 | None |
| Injection of drug into eye | 251 | $138,822 | $119 |
| Imaging of retina | 816 | $85,255 | $39 |
See all 15 services
| Injection, aflibercept, 1 mg | 128 | $717,754 | None |
| Injection, faricimab-svoa, 0.1 mg | 34 | $264,413 | None |
| Injection, aflibercept hd, 1 mg | 19 | $160,558 | None |
| Injection of drug into eye | 251 | $138,822 | $119 |
| Imaging of retina | 816 | $85,255 | $39 |
| Short return visit (20+ min) | 610 | $72,404 | $77 |
| Unclassified drugs | 15 | $65,476 | None |
| Return visit (30+ min) | 307 | $44,199 | $117 |
| Compounded drug, not otherwise classified | 139 | $39,678 | None |
| New patient visit (45+ min) | 60 | $8,687 | $145 |
| Long return visit (40+ min) | 30 | $5,201 | $158 |
| Photography of the retina | 107 | $4,943 | $36 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 189 | $3,695 | $15 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 18 | $3,159 | $175 |
| New patient visit (30+ min) | 19 | $1,726 | $91 |
Procedures Medicare counted
| Cataract surgery | 1-10 | None |
Who their Medicare patients are
844 Original Medicare patients in 2024. Average age 78 · Under 65 2% · 85 and older 24% · Women 56% · Also on Medicaid 8% · Health risk score 1.06. At or below the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 66% · Diabetes 24% · Coronary heart disease 22% · Chronic kidney disease 22% · Atrial fibrillation 16% · Cancer 14% · Depression 14% · Heart failure 10% · COPD 7% · Stroke 6% · Dementia 5%.
The office billed $5,809,073, Medicare allowed $2,158,054 and paid $1,688,412; for 18,422 services of 51 kinds; $1,169,447 of it was for drugs given in the office and $518,965 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 844 | 18,422 | 78 | 1.06 | $5,809,073 | $1,688,412 |
| 2023 | 801 | 16,517 | 78 | 1.07 | $4,931,899 | $1,494,332 |
| 2022 | 745 | 9,798 | 78 | 1.03 | $4,339,317 | $1,434,935 |
| 2021 | 687 | 7,135 | 78 | 1.10 | $3,974,051 | $1,497,385 |
| 2020 | 550 | 5,724 | 78 | 1.23 | $3,151,898 | $1,143,676 |
| 2019 | 595 | 5,164 | 78 | 1.29 | $2,622,057 | $870,219 |
| 2018 | 588 | 4,477 | 77 | 1.26 | $2,165,339 | $747,068 |
| 2017 | 555 | 3,968 | 77 | 1.16 | $1,846,310 | $663,043 |
| 2016 | 467 | 2,708 | 77 | 1.23 | $1,421,419 | $511,133 |
| 2015 | 318 | 1,482 | 72 | 1.67 | $328,237 | $87,098 |
| 2014 | 311 | 1,453 | 71 | 1.76 | $356,852 | $99,656 |
| 2013 | 295 | 1,311 | 71 | 1.71 | $338,971 | $93,645 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 13 services
| Injection, aflibercept, 1 mg | 109 | $754,794 | None |
| Injection, faricimab-svoa, 0.1 mg | 29 | $252,234 | None |
| Injection of drug into eye | 246 | $138,696 | $125 |
| Imaging of retina | 786 | $83,641 | $40 |
| Short return visit (20+ min) | 618 | $79,426 | $79 |
| Compounded drug, not otherwise classified | 146 | $40,871 | None |
| Return visit (30+ min) | 257 | $34,601 | $116 |
| New patient visit (45+ min) | 44 | $6,638 | $151 |
| Long return visit (40+ min) | 25 | $4,533 | $174 |
| Photocoagulation treatment to prevent detachment of retina | 12 | $3,604 | $257 |
| Photography of the retina | 73 | $3,126 | $36 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 17 | $2,491 | $147 |
| New patient visit (30+ min) | 23 | $1,692 | $74 |
2022: 14 services
| Injection, aflibercept, 1 mg | 109 | $848,768 | None |
| Injection of drug into eye | 227 | $140,634 | $124 |
| Imaging of retina | 733 | $81,599 | $40 |
| Short return visit (20+ min) | 583 | $72,835 | $78 |
| Injection, faricimab-svoa, 0.1 mg | 22 | $64,457 | None |
| Compounded drug, not otherwise classified | 138 | $44,867 | None |
| Return visit (30+ min) | 233 | $31,139 | $111 |
| Unclassified biologics | 15 | $22,118 | None |
| Repair of detached retina with drainage and removal of eye fluid between lens and retina | 11 | $12,576 | $1,143 |
| New patient visit (45+ min) | 47 | $6,634 | $141 |
| Photography of the retina | 115 | $4,793 | $37 |
| Long return visit (40+ min) | 22 | $3,408 | $155 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 23 | $3,104 | $135 |
| New patient visit (30+ min) | 20 | $1,677 | $84 |
2021: 12 services
| Injection, aflibercept, 1 mg | 92 | $956,290 | None |
| Injection of drug into eye | 211 | $144,234 | $126 |
| Imaging of retina | 645 | $80,080 | $41 |
| Short return visit (20+ min) | 516 | $73,653 | $81 |
| Compounded drug, not otherwise classified | 134 | $49,271 | None |
| Return visit (30+ min) | 303 | $38,469 | $108 |
| Photocoagulation treatment to prevent detachment of retina | 12 | $6,666 | $556 |
| New patient visit (45+ min) | 43 | $5,704 | $133 |
| Photography of the retina | 101 | $4,449 | $39 |
| Long return visit (40+ min) | 20 | $3,367 | $168 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 24 | $3,044 | $127 |
| New patient visit (30+ min) | 15 | $1,447 | $96 |
2020: 9 services
| Injection, aflibercept, 1 mg | 76 | $687,883 | None |
| Injection of drug into eye | 197 | $106,070 | $106 |
| Return visit (30+ min) | 498 | $79,526 | $94 |
| Imaging of retina | 514 | $63,155 | $40 |
| Compounded drug, not otherwise classified | 134 | $43,221 | None |
| Short return visit (20+ min) | 66 | $5,214 | $70 |
| New patient visit (45+ min) | 30 | $4,501 | $150 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 35 | $3,730 | $107 |
| Photography of the retina | 66 | $3,002 | $44 |
2019: 12 services
| Injection, aflibercept, 1 mg | 60 | $450,261 | None |
| Injection of drug into eye | 180 | $88,582 | $102 |
| Return visit (30+ min) | 533 | $84,876 | $92 |
| Imaging of retina | 544 | $60,250 | $39 |
| Compounded drug, not otherwise classified | 124 | $30,019 | None |
| Removal of membrane of retina with removal of internal limiting membrane of retina | 12 | $13,367 | $1,114 |
| New patient visit (45+ min) | 41 | $5,374 | $131 |
| Short return visit (20+ min) | 46 | $3,660 | $69 |
| Photography of the retina | 45 | $2,517 | $49 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 23 | $2,100 | $91 |
| Injection, bevacizumab, 10 mg | 13 | $1,815 | None |
| New patient visit (30+ min) | 12 | $1,030 | $86 |
2018: 9 services
| Injection, aflibercept, 1 mg | 54 | $415,327 | None |
| Return visit (30+ min) | 531 | $89,056 | $91 |
| Injection of drug into eye | 145 | $67,433 | $98 |
| Imaging of retina | 533 | $55,826 | $39 |
| Compounded drug, not otherwise classified | 104 | $19,703 | None |
| Photocoagulation treatment to prevent detachment of retina | 11 | $6,176 | $515 |
| New patient visit (45+ min) | 41 | $5,160 | $126 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 20 | $1,739 | $87 |
| Short return visit (20+ min) | 20 | $1,133 | $54 |
2017: 8 services
| Injection, aflibercept, 1 mg | 54 | $386,339 | None |
| Return visit (30+ min) | 501 | $83,767 | $92 |
| Injection of drug into eye | 139 | $60,021 | $98 |
| Imaging of retina | 494 | $48,492 | $38 |
| Compounded drug, not otherwise classified | 102 | $16,106 | None |
| New patient visit (45+ min) | 41 | $5,434 | $133 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 36 | $3,177 | $86 |
| Short return visit (20+ min) | 23 | $1,538 | $59 |
2016: 11 services
| Injection, aflibercept, 1 mg | 52 | $317,482 | None |
| Return visit (30+ min) | 379 | $51,732 | $96 |
| Injection of drug into eye | 108 | $41,859 | $100 |
| Imaging of retina | 317 | $31,049 | $43 |
| Compounded drug, not otherwise classified | 62 | $9,796 | None |
| Established patient complete exam of visual system | 77 | $9,503 | $119 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 61 | $8,084 | $111 |
| Short return visit (20+ min) | 60 | $5,815 | $68 |
| New patient visit (45+ min) | 15 | $2,025 | $135 |
| Established patient problem focused exam of visual system | 25 | $1,716 | $64 |
| New patient visit (30+ min) | 12 | $878 | $73 |
2015: 7 services
| Injection of drug into eye | 64 | $17,911 | $78 |
| Return visit (30+ min) | 167 | $14,085 | $52 |
| Short return visit (20+ min) | 207 | $12,400 | $40 |
| Imaging of retina | 229 | $12,335 | $22 |
| New patient visit (30+ min) | 30 | $1,300 | $43 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 12 | $480 | $37 |
| Photography of the retina | 15 | $284 | $19 |
2014: 9 services
| Return visit (30+ min) | 249 | $30,681 | $59 |
| Injection of drug into eye | 46 | $13,808 | $78 |
| Imaging of retina | 217 | $12,313 | $23 |
| Short return visit (20+ min) | 57 | $2,381 | $35 |
| New patient visit (30+ min) | 24 | $1,318 | $55 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 19 | $727 | $38 |
| 2d ultrasound scan of eye tissue and structures | 11 | $505 | $42 |
| Established patient problem focused exam of visual system | 12 | $498 | $38 |
| Photography of the retina | 13 | $264 | $20 |
2013: 10 services
| Return visit (30+ min) | 235 | $29,042 | $57 |
| Injection of drug into eye | 44 | $10,926 | $81 |
| Imaging of retina | 190 | $10,494 | $22 |
| New patient visit (45+ min) | 20 | $1,886 | $94 |
| Established patient problem focused exam of visual system | 30 | $1,348 | $41 |
| New patient visit (30+ min) | 16 | $922 | $58 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 22 | $889 | $37 |
| Short return visit (20+ min) | 13 | $738 | $39 |
| Established patient complete exam of visual system | 17 | $657 | $36 |
| Photography of the retina | 12 | $197 | $16 |
Medicaid work
$2,844 in 2024
Medicaid paid $2,844 for 165 billed services this clinician did in 2024, up to 23 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 125 | $1,736 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 40 | $1,107 |
| 2024 | 165 | 2 | 23 | $2,844 |
| 2023 | 408 | 3 | 26 | $7,235 |
| 2022 | 284 | 3 | 23 | $8,564 |
| 2021 | 325 | 3 | 22 | $7,435 |
| 2020 | 95 | 2 | 19 | $1,556 |
| 2019 | 89 | 1 | 17 | $2,968 |
| 2018 | 189 | 3 | 21 | $7,644 |
See the largest Medicaid services in earlier years
2023
| Intravitreal injection of a pharmacologic agent (separate procedure) | 139 | $4,791 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 245 | $2,099 |
| Short return visit (20+ min) | 24 | $345 |
2022
| Intravitreal injection of a pharmacologic agent (separate procedure) | 102 | $6,667 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 170 | $1,714 |
| Short return visit (20+ min) | 12 | $183 |
2021
| Intravitreal injection of a pharmacologic agent (separate procedure) | 91 | $4,072 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 221 | $2,963 |
| Short return visit (20+ min) | 13 | $399 |
2020
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 70 | $1,100 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 25 | $456 |
2019
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 89 | $2,968 |
2018
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 150 | $4,832 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 12 | $1,558 |
| Return visit (30+ min) | 27 | $1,255 |
Drugs they prescribed that Part D paid
$25,523
Pharmacies billed $25,523 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
238 generic and 133 brand-name prescriptions · $25,523 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Prednisolone Acetate | 106 | $6,967 | $66 |
| Bromfenac | 35 | $4,750 | $136 |
| Brimonidine Tartrate-Timolol | 12 | $1,916 | $160 |
| Ketorolac Tromethamine | 67 | $1,262 | $19 |
| Dorzolamide | 24 | $302 | $13 |
See all 7 drugs
| Prednisolone Acetate | 106 | $6,967 | $66 |
| Bromfenac | 35 | $4,750 | $136 |
| Brimonidine Tartrate-Timolol | 12 | $1,916 | $160 |
| Ketorolac Tromethamine | 67 | $1,262 | $19 |
| Dorzolamide | 24 | $302 | $13 |
| Polymyxin B Sul-Trimethoprim | 35 | $285 | $8 |
| Brimonidine | 27 | $196 | $7 |
Year by year
| 2024 | 371 | 104 | None | 36% | $25,523 |
| 2023 | 308 | 68 | 0% (0) | 42% | $26,315 |
| 2022 | 320 | 79 | None | 46% | $31,084 |
| 2021 | 264 | 71 | None | 47% | $31,647 |
| 2020 | 295 | 73 | None | 55% | $33,532 |
| 2019 | 258 | 57 | None | 58% | $29,438 |
| 2018 | 240 | 60 | None | 66% | $28,870 |
| 2017 | 276 | 57 | None | 63% | $35,707 |
| 2016 | 162 | 49 | None | 57% | $12,469 |
| 2015 | 225 | 44 | None | 50% | $20,957 |
| 2014 | 269 | 61 | None | 48% | $19,334 |
| 2013 | 295 | 60 | None | 55% | $26,370 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 7 drugs
| Prednisolone Acetate | 88 | $5,551 | $63 |
| Prolensa | 11 | $4,082 | $371 |
| Bromfenac | 15 | $3,534 | $236 |
| Ketorolac Tromethamine | 62 | $1,421 | $23 |
| Dorzolamide | 48 | $1,008 | $21 |
| Brimonidine | 19 | $369 | $19 |
| Polymyxin B Sul-Trimethoprim | 17 | $155 | $9 |
2022: 6 drugs
| Prolensa | 17 | $8,133 | $478 |
| Prednisolone Acetate | 85 | $5,576 | $66 |
| Ketorolac Tromethamine | 71 | $2,427 | $34 |
| Dorzolamide | 33 | $754 | $23 |
| Brimonidine | 26 | $585 | $23 |
| Polymyxin B Sul-Trimethoprim | 22 | $218 | $10 |
2021: 6 drugs
| Prolensa | 11 | $6,030 | $548 |
| Prednisolone Acetate | 52 | $3,301 | $63 |
| Brimonidine | 41 | $2,525 | $62 |
| Ketorolac Tromethamine | 39 | $1,088 | $28 |
| Dorzolamide | 22 | $752 | $34 |
| Polymyxin B Sul-Trimethoprim | 16 | $160 | $10 |
2020: 6 drugs
| Prednisolone Acetate | 62 | $3,862 | $62 |
| Brimonidine | 24 | $2,545 | $106 |
| Ketorolac Tromethamine | 55 | $1,925 | $35 |
| Dorzolamide | 48 | $1,695 | $35 |
| Latanoprost | 14 | $260 | $19 |
| Polymyxin B Sul-Trimethoprim | 15 | $123 | $8 |
2019: 8 drugs
| Azopt | 28 | $11,531 | $412 |
| Combigan | 15 | $3,945 | $263 |
| Prednisolone Acetate | 51 | $3,797 | $74 |
| Brimonidine | 15 | $1,723 | $115 |
| Ketorolac Tromethamine | 28 | $1,013 | $36 |
| Dorzolamide | 19 | $683 | $36 |
| Polymyxin B Sul-Trimethoprim | 30 | $256 | $9 |
| Latanoprost | 11 | $148 | $13 |
2018: 7 drugs
| Azopt | 37 | $11,738 | $317 |
| Prednisolone Acetate | 52 | $4,540 | $87 |
| Brimonidine | 18 | $1,536 | $85 |
| Ketorolac Tromethamine | 28 | $1,233 | $44 |
| Latanoprost | 15 | $177 | $12 |
| Timolol Maleate | 11 | $172 | $16 |
| Polymyxin B Sul-Trimethoprim | 19 | $143 | $8 |
2017: 9 drugs
| Ilevro | 27 | $7,537 | $279 |
| Bromfenac | 18 | $5,638 | $313 |
| Azopt | 20 | $5,330 | $266 |
| Prednisolone Acetate | 56 | $4,765 | $85 |
| Pataday | 13 | $2,172 | $167 |
| Durezol | 11 | $1,789 | $163 |
| Brimonidine | 25 | $1,482 | $59 |
| Latanoprost | 20 | $200 | $10 |
| Polymyxin B Sul-Trimethoprim | 19 | $181 | $10 |
2016: 4 drugs
| Prednisolone Acetate | 40 | $2,738 | $68 |
| Atropine Sulfate | 16 | $642 | $40 |
| Latanoprost | 15 | $224 | $15 |
| Polymyxin B Sul-Trimethoprim | 15 | $120 | $8 |
2015: 6 drugs
| Nevanac | 38 | $8,555 | $225 |
| Prednisolone Acetate | 41 | $2,631 | $64 |
| Bromfenac | 15 | $1,861 | $124 |
| Latanoprost | 33 | $563 | $17 |
| Brimonidine | 12 | $470 | $39 |
| Timolol Maleate | 19 | $174 | $9 |
2014: 7 drugs
| Prednisolone Acetate | 47 | $3,580 | $76 |
| Nevanac | 18 | $3,103 | $172 |
| Durezol | 16 | $1,990 | $124 |
| Brimonidine | 12 | $1,163 | $97 |
| Latanoprost | 51 | $1,012 | $20 |
| Dorzolamide-Timolol | 31 | $718 | $23 |
| Timolol Maleate | 14 | $115 | $8 |
2013: 8 drugs
| Nevanac | 49 | $8,707 | $178 |
| Brimonidine | 42 | $3,388 | $81 |
| Durezol | 18 | $1,991 | $111 |
| Prednisolone Acetate | 43 | $1,347 | $31 |
| Dorzolamide-Timolol | 21 | $766 | $36 |
| Latanoprost | 25 | $555 | $22 |
| Ketorolac Tromethamine | 19 | $412 | $22 |
| Timolol Maleate | 18 | $183 | $10 |
Money from drug and device companies
$27 in 2025
| 2025 | 1 | 1 | None | $27 |
| 2023 | 1 | 1 | None | $294 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Harrow Eye | Iheezo | $27 | 1 payment
|
See the published payment
| Harrow Eye | Meals · 2025-04-08 | Iheezo | $27 |
See earlier years (2023)
2023: $294
| Carl Zeiss Meditec USA | Cirrus 5000 With Angioplex | $294 | 1 payment
|
Professional record
- NPI
- 1235157207
- Licence
- CA A105147, WA MD60022492California A105147: Current · expires 2028-03-31Washington MD.MD.60022492: Active
- Trained
- Washington University School of Medicine, 2002
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- WA 1235157207
- Taxonomy
- Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2006-07-18
- NPI last updated
- 2020-05-29
- NPI record certified
- 2020-05-29
This is when the NPI record was last certified, not a medical board exam.